<DOC>
	<DOCNO>NCT00442754</DOCNO>
	<brief_summary>Vaccination autologous dendritic cell pulse allogeneic melanoma cell lysate ( MelCancerVac ) combination Cox-2 inhibitor celecoxib treatment patient advance metastatic non-small cell lung cancer ( NSCLC ) . Adjuvant Aldara cream use adjuvant induction inflammation injection site , lymphocyte growth factor interleukin-2 ( IL-2 ) give s.c. injection . The treatment aim boost patient 's specific immune system cancer cell .</brief_summary>
	<brief_title>Dendritic Cells Lung Cancer</brief_title>
	<detailed_description>Vaccination autologous dendritic cell pulse allogeneic melanoma cell lysate ( MelCancerVac ) combination Cox-2 inhibitor celecoxib treatment patient advance metastatic non-small cell lung cancer ( NSCLC ) . Adjuvant Aldara cream use adjuvant induction inflammation injection site , lymphocyte growth factor interleukin-2 ( IL-2 ) give s.c. injection . The treatment aim boost patient 's specific immune system cancer cell . Patients disseminate , inoperable NSCLC chemotherapy patient want chemotherapy systemic treatment offer . Primary objective : measure antigen specific immunological reaction vaccine antigens patient ' immune system vivo vitro . Secondary objective : estimate patient ' survival time , estimate response accord RECIST criterion , estimate patient ' quality life study period . The study design open , phase II , clinical study carry accordance present protocol , ICH/GCP Guidelines national , regulatory requirement . The first patient expect include towards end 2006 . Inclusion period continue 2 year . Follow-up continue approx . 6 month prior report . Fifty patient plan inclusion . In case none first fourteen ( 14 ) evaluable patient respond , inclusion study discontinue .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>dendritic cell</keyword>
	<keyword>tumor vaccine</keyword>
	<keyword>NSCLC</keyword>
</DOC>